Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas

被引:179
作者
Yamashita, F
Tanaka, M
Satomura, S
Tanikawa, K
机构
[1] KURUME UNIV,SCH MED,DEPT MED 2,KURUME,FUKUOKA 830,JAPAN
[2] WAKO PURE CHEM IND LTD,OSAKA RES LABS,AMAGASAKI,HYOGO,JAPAN
关键词
D O I
10.1016/S0016-5085(96)70067-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) has been reported to be a useful marker in the early diagnosis of hepatocellular carcinoma (HCC), The aim of this study was to evaluate the prognostic value of AFP-L3 for HCC, Methods: Fifty-five patients with HCC whose AFP-L3 levels were negative before initial therapy were studied, AFP-L3 levels were measured by lectin-affinity electrophoresis coupled with antibody-affinity blotting. Results: Of the 55 patients, 28, 15, and 12 underwent percutaneous ethanol injection, transcatheter arterial embolization, and hepatectomy, respectively. Thirty-two (58.2%) of the 55 patients maintained a negative AFP-L3 status during the study, and 23 patients (41.8%) became positive for AFP-L3 during posttreatment observation, Multiple recurrences of HCC and portal vein tumor thrombus were observed significantly more often in patients with positive AFP-L3 than in those with negative AFP-LS status (P < 0.0001). In contrast, most patients with negative AFP-LB had solitary recurrences of HCC without portal vein tumor thrombus, Overall survival was significantly lower in patients with positive AFP-L3 than in those with negative AFP-LB status (P = 0.0006), Cox's proportional hazards model identified that AFP-LB was an independent prognostic factor (P = 0.0005), Conclusions: AFP-L3 seems to be a significant marker of poor prognosis for HCC.
引用
收藏
页码:996 / 1001
页数:6
相关论文
共 46 条
[21]   TREATMENT OF HEPATOCELLULAR-CARCINOMA BY TRANSCATHETER ARTERIAL EMBOLIZATION COMBINED WITH INTRAARTERIAL INFUSION OF A MIXTURE OF CISPLATIN AND ETHIODIZED OIL [J].
KASUGAI, H ;
KOJIMA, J ;
TATSUTA, M ;
OKUDA, S ;
SASAKI, Y ;
IMAOKA, S ;
FUJITA, M ;
ISHIGURO, S .
GASTROENTEROLOGY, 1989, 97 (04) :965-971
[22]  
KUROMATSU R, 1993, LIVER, V13, P177
[23]  
LIVARGHI T, 1986, RADIOLOGY, V161, P309
[24]  
LIVARGHI T, 1990, CARDIOVASC INTERVENT, V13, P146
[25]  
Liver Cancer Study Group of Japan, 1990, Ann Surg, V211, P277
[26]   LIVER-TRANSPLANTATION FOR PRIMARY HEPATOCELLULAR-CARCINOMA - TUMOR SIZE AND NUMBER DETERMINE OUTCOME [J].
MCPEAKE, JR ;
OGRADY, JG ;
ZAMAN, S ;
PORTMANN, B ;
WIGHT, DGD ;
TAN, KC ;
CALNE, RY ;
WILLIAMS, R .
JOURNAL OF HEPATOLOGY, 1993, 18 (02) :226-234
[27]   TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
OKEN, MM ;
CREECH, RH ;
TORMEY, DC ;
HORTON, J ;
DAVIS, TE ;
MCFADDEN, ET ;
CARBONE, PP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :649-655
[28]  
OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO
[29]  
2-E
[30]   HEPATOCELLULAR-CARCINOMA - RECENT PROGRESS [J].
OKUDA, K .
HEPATOLOGY, 1992, 15 (05) :948-963